Trodelvy’s Phase III Breast Cancer Results Raise More Questions Than Answers

Gilead is staying mum about the TROPiCS-02 data, which is fueling speculation that the drug’s benefit may have been modest.

Cancer cells on scientific background.3d illustration
Gilead announced results of the Phase III TROPiCS-02 study of Trodelvy in HR+/HER2- metastatic breast cancer • Source: Shutterstock

While Gilead Sciences, Inc.’s Phase III TROPiCS-02 study of Trodelvy (sacituzumab govitecan-hziy) technically met its primary endpoint in third-line HR-positive/HER2-negative metastatic breast cancer (HR+/HER2- mBC), public statements by the company and a lack of details about progression-free survival (PFS) and overall survival (OS) data raised uncertainty about whether they would be enough to drive commercial adoption.

Gilead announced the study results on 7 March, but did not disclose any data, saying instead that the trial met...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.